LEXINGTON, Mass., March 12, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation

- AGEN1181 +/- balstilimab (anti-PD-1) reveals a complete response and new partial responses in phase 1 clinical trial - Balstilimab & zalifrelimab (anti-CTLA-4) demonstrate 26.5% response rates in an all-comer (non-biomarker selected) population with advanced cervical cancer - FDA grants Fast

$15.1M Milestone from HealthCare Royalty Partners LEXINGTON, Mass., March 10, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, announced the triggering of a $15.1M milestone payment

LEXINGTON, Mass., March 3, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will release its fourth quarter and full year 2019 financial results before the market

- Balstilimab and zalifrelimab combination yield >20% response rates - Balstilimab and zalifrelimab combination has best-in-class potential for the treatment of second-line cervical cancer - On track to submit 2 BLAs for these agents in 2020 - Low-dose AGEN1181 monotherapy demonstrated a confirmed

LEXINGTON, Mass., Feb. 6, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced it will hold an Investor Day Thursday, February 20, 2020.

LEXINGTON, Mass., Jan. 9, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment of Dr. Jennifer Buell to President and COO.

- AGEN1223 is a novel bi-specific designed to selectively deplete regulatory T cells in the tumor microenvironment - First patient dosed; combinations with other IO agents planned for 2020 LEXINGTON, Mass., Jan. 8, 2020 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with

LEXINGTON, Mass., Dec. 19, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, today announced the first patient dosed with AGEN1181, an anti-CTLA-4 antibody, in

LEXINGTON, Mass., Nov. 12, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced that it will host an R&D Day on November 15, 2019.

- UroGen receives rights to zalifrelimab to be used in its proprietary sustained release formulation for patients with high-grade non-muscle invasive bladder cancer LEXINGTON, Mass., Nov. 11, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of

- PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies clear INDs & advance into clinical trials - NexGen CTLA-4 (AGEN1181) advances to 3rd cohort;

LEXINGTON, Mass., Oct. 31, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its third quarter 2019 financial results before the market opens on Monday, November 4, 2019.

LEXINGTON, Mass., Sept. 30, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies 1  and cancer vaccines, announced today that Jennifer Buell, PhD, Chief Operating Officer of Agenus, present an

FDA acceptance of IND filing for AGEN1223; triggers cash milestone AGEN1223 is a first-in-class bi-specific designed to deplete regulatory T cells in tumor microenvironment LEXINGTON, Mass., August 28, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a

Invented by Agenus, licensed to Gilead, GS-1423 is a bi-functional antibody designed to block tumor escape mechanisms Supply supports ongoing Phase 1 of GS-1423 in patients with advanced solid tumors LEXINGTON, Mass., August 21, 2019 / PRNewswire / -- Agenus Inc.

- FDA acceptance of IND filing for AGEN2373 triggers payment and clears path to begin clinical trials - The payment represents the second milestone in Gilead partnership achieved in 2019 LEXINGTON, Mass., Aug. 8, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O)

- Enrollment of CTLA-4 & PD-1 trials on track; data expected 2H2019 - Second generation CTLA-4 advances in clinic; data expected 2H2019 - Launched commercial readiness with head of commercial on board - $15M in cash milestones triggered; new compounds move towards clinic - GSK's Shingrix sales

LEXINGTON, Mass., Aug. 6, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market opens on Thursday, August 8, 2019.

LEXINGTON, Mass., July 18, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced the appointment of Don Vidic as Vice President, Head

LEXINGTON, Mass., June 13, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , invites investors and the general public to attend its annual meeting of stockholders

- Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - GSK's Shingrix sales continue to grow; projected to be ~$1.3Bn in 2019 LEXINGTON, Mass.

LEXINGTON, Mass., May 3, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , will release its first quarter 2019 financial results before the market opens

LEXINGTON, Mass., April 2, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies 1 , today announced that the first patient was dosed in the  clinical trial  of its

- Dr. Manuel Hidalgo, MD, PhD as Strategic Advisor - Paulo Moreira as Global Head of Clinical Operations LEXINGTON, Mass., March 21, 2019 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell